Xuefeng Fang
Welcome,         Profile    Billing    Logout  
 13 Trials 
34 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yuan, Ying
NCT05362617: mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy

Recruiting
3
328
RoW
FOLFIRI
Second Affiliated Hospital, School of Medicine, Zhejiang University
Metastatic Colorectal Cancer
12/22
12/23
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
NCT05171660: Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Recruiting
3
436
RoW
Sintilimab Injection, bevacizumab, Oxaliplatin, Capecitabine, Control Test, XELOX + Bevacizumab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Colorectal Cancer Stage IV
12/24
06/25
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
NCT05466318: ChiCGB vs BEAM in High-risk or R/R Lymphomas

Recruiting
3
306
RoW
Chidamide, Cladribine, Gemcitabine, Busulfan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous hematopoietic stem cell transplant
Sichuan University
Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell
12/25
12/25
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Recruiting
3
680
RoW
JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Shanghai Junshi Bioscience Co., Ltd.
Gastric or Esophagogastric Junction Adenocarcinoma
03/26
07/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
NCT05409417: Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status

Recruiting
2/3
40
RoW
Experimental drug, Tilelizumab combined with chemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
Colorectal Cancer, Liver Metastases
02/24
09/24
BEVTOR, NCT04527068: QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer

Not yet recruiting
2
50
RoW
Bevacizumab, QL1101, Tripleitriumab, JS001
Second Affiliated Hospital, School of Medicine, Zhejiang University, Qilu Pharmaceutical Co., Ltd., Shanghai Junshi Bioscience Co., Ltd.
Refractory Metastatic Colorectal Cancer, pMMR, MSS
09/21
02/22
BBCAPX-II, NCT04194359: Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer

Active, not recruiting
2
25
RoW
Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine
Second Affiliated Hospital, School of Medicine, Zhejiang University
Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable
11/22
12/23
RALOXBTC, NCT05148143: RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor

Recruiting
2
50
RoW
Raltitrexed combined with oxaplatin, Sai Wei Jian
Second Affiliated Hospital, School of Medicine, Zhejiang University
Cholangioadenoma
12/22
12/23
NCT04733963: Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

Recruiting
2
112
RoW
Fruquintinib Plus Capecitabine, Bevacizumab Plus Capecitabine
Second Affiliated Hospital, School of Medicine, Zhejiang University
Colorectal Cancer
01/23
02/23
NCT05160896: SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

Recruiting
2
90
RoW
Raltitrexed, Sai Wei Jian, Irinotecan, CPT-11, Bevacizumab, Avastin, Cetuximab, ERBITUX
Second Affiliated Hospital, School of Medicine, Zhejiang University
Advanced Metastatic Colorectal Cancer
06/23
06/23
NCT06134765: Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer

Not yet recruiting
2
89
RoW
Bemalenograstim alfa, F-627
Second Affiliated Hospital, School of Medicine, Zhejiang University
Colorectal Cancer, Pancreatic Cancer
10/24
03/25
NCT05785325: RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer

Recruiting
2
30
RoW
RC48-ADC plus Bevacizumab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Colorectal Cancer
12/23
12/24
NCT05894837: Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases

Not yet recruiting
2
30
RoW
Serplulimab+Regorafenib, Hepatic Artery Bicarbonate Infusion
Second Affiliated Hospital, School of Medicine, Zhejiang University
Colorectal Cancer, Liver Metastases
06/24
06/25
NCT05555901: The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer

Recruiting
2
116
RoW
Fruquintinib+ chemotherapy, Bevacizumab+ chemotherapy
Fudan University
Metastatic Colorectal Cancer
09/25
09/25
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
02/25
05/25
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Recruiting
1/2
68
RoW
T3011 high dose, T3011 middle dose, T3011 low dose
Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumors
12/25
05/26
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Recruiting
1/2
133
RoW
KC1036
Beijing Konruns Pharmaceutical Co., Ltd.
Digestive System Tumors
10/25
12/25
NCT05338957: A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Recruiting
1/2
30
RoW
MRG002+HX008
Shanghai Miracogen Inc.
Advanced Malignant Solid Tumors
06/24
12/24
CSG-1906-101, NCT05857332: SG1906 for CLDN18.2-Positive Solid Tumors

Recruiting
1
60
RoW
SG1906
Hangzhou Sumgen Biotech Co., Ltd.
Locally Advanced Unresectable or Metastatic Solid Tumors
02/25
08/25
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Recruiting
1
72
RoW
ABM-1310
ABM Therapeutics Shanghai Company Limited
Advanced Solid Tumor, BRAF V600 Mutation
08/25
08/25
NCT04819516: Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer

Recruiting
1
10
RoW
high-intensity focused ultrasound therapy, Toripalimab, Regorafenib
Second Affiliated Hospital, School of Medicine, Zhejiang University
Colorectal Cancer
12/25
12/25
NCT06043466: A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Recruiting
1
30
RoW
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd, Zhejiang University
Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer, Non-small Cell Lung Cancer, Breast Cancer, Bile Duct Cancer
12/26
12/27
INSPPIRE 2, NCT06651580: Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, Study

Recruiting
N/A
1600
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Pancreatitis, Exocrine Pancreas Carcinoma, Recurrent Acute Pancreatitis
02/27
02/27
NCT03958435: Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery

Recruiting
N/A
20000
RoW
Second Affiliated Hospital, School of Medicine, Zhejiang University
Stage II Colon Cancer, Stage III Colon Cancer, Adjuvant Therapy
10/22
12/23
NCT04961125: Multicenter Study on the Pathogenic Germline Gene Variants of Colorectal Polyposis in China

Recruiting
N/A
200
RoW
germline variants
Second Affiliated Hospital, School of Medicine, Zhejiang University
Colorectal Polyposis
12/22
12/24
NCT06101030: Comparing Use of Incentive Spirometry with and Without Reminder

Recruiting
N/A
500
US
Signal On
Tidal Medical Technologies
Post Operative
03/25
07/25
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

Recruiting
N/A
958
Canada, US
Tendyne Mitral Valve System, MitraClip System
Abbott Medical Devices
Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
05/24
06/28
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Active, not recruiting
N/A
150
US
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure, Inc.
Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
06/24
06/26
NCT03460769: Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

Recruiting
N/A
600
US
Data Management and Monitoring
M.D. Anderson Cancer Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pancreatic Cancer, Chronic Pancreatitis, Diabetes Mellitus Type 3c
06/25
06/25
FANG, XUEFENG
NCT05171660: Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Recruiting
3
436
RoW
Sintilimab Injection, bevacizumab, Oxaliplatin, Capecitabine, Control Test, XELOX + Bevacizumab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Colorectal Cancer Stage IV
12/24
06/25
BBCAPX-II, NCT04194359: Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer

Active, not recruiting
2
25
RoW
Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine
Second Affiliated Hospital, School of Medicine, Zhejiang University
Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable
11/22
12/23

Download Options